MedTrace Logo

Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD

NCT00274053 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 555

Last updated 2013-11-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of a 9-month treatment of tiotropium (SPIRIVA®) 18 mcg once daily on Health Related Quality of Life and lung function in patients with a Chronic Obstructive Pulmonary Disease.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

tiotropium

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · BI France S.A.S.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2004-04-30
Completion
2004-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274053 on ClinicalTrials.gov